OSE Immunotherapeutics — Refocusing for the next phase
OSE Immunotherapeutics’ H125 results, the first since the board restructuring, reflected normalised operations typical of a clinical-stage biotech,...
216 Views
OSE Immunotherapeutics — Updated cash position; new collaboration
While OSE Immunotherapeutics’ H125 results were previously due to be presented in September, they are now scheduled for 15 October 2025 to allow...
391 Views
OSE Immunotherapeutics — Spotlight on OSE’s diverse clinical pipeline
OSE Immunotherapeutics has made tangible progress across its clinical development pipeline, creating positive momentum, in our view. In...
322 Views
OSE Immunotherapeutics — New UC biomarker underpins growth strategy
OSE has announced plans to strengthen its growth strategy and accelerate the key pillars of its pipeline, covering immuno-inflammation and...
278 Views
OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential
OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to...
300 Views